Edap Tms (NASDAQ:EDAP)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Friday.

The analysts wrote, “Valuation and risks to price target achievement. We reiterate our Buy rating and $6 price target. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based solely on the HS-110 opportunity in NSCLC, and only on the U.S. market based on what we consider to be modest penetration rates.””

A number of other research firms have also weighed in on EDAP. TheStreet lowered Edap Tms from a “c” rating to a “d+” rating in a research report on Friday, September 28th. Zacks Investment Research lowered Edap Tms from a “hold” rating to a “sell” rating in a research report on Friday, September 7th.

Shares of NASDAQ EDAP opened at $2.34 on Friday. The company has a market capitalization of $71.33 million, a price-to-earnings ratio of -234.00 and a beta of 0.74. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.97 and a current ratio of 2.41. Edap Tms has a 52-week low of $2.07 and a 52-week high of $4.25.

Edap Tms (NASDAQ:EDAP) last announced its earnings results on Wednesday, November 14th. The medical equipment provider reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.02). The company had revenue of $9.47 million for the quarter, compared to analyst estimates of $10.34 million. Edap Tms had a negative return on equity of 2.66% and a negative net margin of 3.55%. Analysts predict that Edap Tms will post -0.03 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Edap Tms stock. Fosun International Ltd acquired a new position in shares of Edap Tms SA (NASDAQ:EDAP) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 170,627 shares of the medical equipment provider’s stock, valued at approximately $526,000. Fosun International Ltd owned 0.59% of Edap Tms at the end of the most recent quarter. Institutional investors and hedge funds own 8.15% of the company’s stock.

About Edap Tms

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

Featured Story: Relative Strength Index

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.